A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Magdalena Czemerska et al.|Blood|2025Cited by 1
Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 studyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2025Cited by 0